UNIVERSITE DE MONTPELLIER;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS);INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);UNIVERSITE DE STRASBOURG
The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.